PixarBio Corporation
Not enough financial coverage to compute a composite score for PXRB. This is typical for foreign-listed ADRs, recent IPOs, or thinly-covered small caps. Live quote, chart, and any available data still render below.
Company
PixarBio Corporation, a specialty pharmaceutical/biotechnology company, focuses on the pre-clinical and clinical development of neurological drug delivery systems for post-operative pain. The company researches and develops delivery systems for drugs, devices, or biologics to treat pain, epilepsy, epilepsy, Parkinson's disease, and spinal cord injury. Its principal product platform is NeuroRelease for the therapeutic release of non-opiate drugs for post-operative, acute, and chronic pain in pre-clinical models.
- CEO
- Francis M. Reynolds
- IPO
- 2023
- Employees
- 30
- HQ
- US
Performance & Tape
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -55.70
- Avg Volume
- 54
Get TickerSpark's AI analysis on PXRB
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our PXRB Coverage
We haven't published any research on PXRB yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate PXRB Report →